AerovectRx Corp., of Atlanta, received notice of allowance for a patent covering claims relating to its platform nebulizer technology, which was licensed from the Centers for Disease Control and Prevention. The technology aims to deliver therapies and vaccines in an easy-to-breathe mist.

Amedex Therapeutics Inc., of Wilsonville, Ore., was issued a patent relating to its NuBiotics portfolio, anti-infective products targeted to bacterial infections and encompassing antibiotic resistant bacteria, such as methicillin-resistant Staphylococcus aureus, and certain viral indications, including avian influenza, Epstein-Barr virus and hepatitis B and C.

ARC Pharmaceuticals Inc., of Vancouver, British Columbia, and the University of British Columbia received U.S. Patent No. 7,163,930, relating to its lead product candidate, ARCAD Instillate, for the prevention and treatment of surgical adhesions. The patent is assigned to UBC and is licensed to ARC through an exclusive worldwide agreement.

Argos Therapeutics, of Durham, N.C., received U.S. Patent NO. 7,169,898, which covers soluble forms of the protein CD83 that could be used for treating disease indications resulting from unabated cellular immune responses, including autoimmune disorders such as multiple sclerosis, as well as for transplant rejection.

Avicena Group Inc., of Palo Alto, Calif., received U.S. Patent No. 7,186,754, titled "Use of Creatine or Creatine Compounds for Skin Preservations," which covers methods and compositions for treating uneven skin pigmentation using topical applications of creatine and carnitine.

Azaya Therapeutics Inc., of San Antonio, was granted a patent for its PSL nanotechnology platform, which is designed to allow for the consistent loading, sizing and stabilizing of active drugs in targeted nanoparticles.